Individualized Cardiac Therapy From Multi-Omics Profiles

Abstract

Precision medicine in cardiology is rapidly evolving, with multi-omics profiling offering the potential to tailor cardiac therapy to individual patients. This review synthesizes current evidence on the application of genomics, transcriptomics, proteomics, metabolomics, and epigenomics in personalizing cardiac care. We discuss the disease burden, underlying mechanisms, risk stratification, clinical manifestations, diagnostic innovations, and therapeutic advancements enabled by multi-omics. The article emphasizes recent breakthroughs, guideline recommendations, and future directions in integrating multi-omics for individualized cardiac therapy, aiming to inform clinicians and drive translational progress.

Introduction

The landscape of cardiology is undergoing a transformative shift from conventional, one-size-fits-all approaches to precision medicine paradigms. Central to this evolution is the advent of multi-omics profiling integrating genomic, transcriptomic, proteomic, metabolomic, and epigenomic data to unravel the complexity of cardiovascular diseases (CVDs) at an unprecedented resolution. These molecular insights enable clinicians to stratify risk, refine diagnoses, and optimize therapeutic regimens tailored to the unique biological context of each patient. In this review, we explore the clinical and scientific relevance of individualized cardiac therapy informed by multi-omics profiles, underpinned by the latest research and guideline-based recommendations.

Epidemiology / Disease Burden

Cardiovascular diseases remain the leading cause of morbidity and mortality worldwide, accounting for an estimated 17.9 million deaths annually. Despite advances in pharmacotherapy and interventional strategies, heterogeneity in disease pathophysiology and therapeutic response persists. Traditional risk models based on population-level data often fail to predict individual outcomes, underscoring the need for more granular, patient-specific approaches. Recent epidemiological studies reveal significant inter-individual variation in disease onset, progression, and treatment efficacy, attributable in part to molecular heterogeneity detectable via multi-omics profiling.

Pathophysiology

Multi-omics technologies have elucidated novel mechanisms underpinning cardiac pathophysiology. Genomic variants in ion channel genes modulate arrhythmia susceptibility, while transcriptomic signatures distinguish heart failure subtypes. Proteomic analysis reveals alterations in signaling cascades, and metabolomic profiling identifies dysregulated pathways in ischemic heart disease. Epigenomic modifications further modulate gene expression in response to environmental factors, contributing to phenotypic diversity. Integrated multi-omics approaches provide comprehensive insights into cellular networks, enabling mechanistic dissection of cardiomyopathies, atherosclerosis, and other CVDs at the systems biology level.

Risk Factors

Beyond traditional risk factors such as hypertension, diabetes, and hyperlipidemia, multi-omics profiling uncovers genetic and molecular risk determinants. Polygenic risk scores (PRS) derived from genome-wide association studies (GWAS) improve stratification of individuals predisposed to coronary artery disease, heart failure, and arrhythmias. Proteomic and metabolomic biomarkers, such as circulating troponins, natriuretic peptides, and sphingolipids, offer dynamic assessment of subclinical disease and predict adverse outcomes. Epigenetic markers, including DNA methylation patterns, have emerged as predictors of incident CVD and therapeutic response, highlighting the potential for early, individualized intervention.

Clinical Features

Multi-omics profiling enhances the phenotypic characterization of cardiac diseases. For example, transcriptomic and proteomic data differentiate heart failure with preserved ejection fraction (HFpEF) from heart failure with reduced ejection fraction (HFrEF), informing tailored management strategies. In inherited arrhythmia syndromes, next-generation sequencing identifies pathogenic variants underlying variable expressivity and penetrance. The integration of multi-omics data with clinical phenotypes enables refined disease subtyping, prognostication, and therapeutic targeting, moving beyond superficial symptom-based classifications.

Diagnosis

Diagnostic accuracy in cardiology is augmented by multi-omics-informed biomarkers and algorithms. Genomic screening identifies monogenic causes of cardiomyopathies, while transcriptomic signatures distinguish inflammatory versus non-inflammatory myocarditis. Proteomic and metabolomic panels are under investigation for early detection of acute coronary syndromes and heart failure decompensation. Machine learning models trained on multi-omics datasets integrate with imaging and clinical data to enhance diagnostic precision, reduce misclassification, and enable real-time risk assessment at the point of care.

Treatment & Management

Individualized cardiac therapy is increasingly feasible with the integration of multi-omics profiles into clinical decision-making. Pharmacogenomics guides selection and dosing of anticoagulants, antiplatelet agents, and statins, mitigating adverse drug reactions and optimizing efficacy. Proteomic and metabolomic markers inform titration of heart failure therapies, while transcriptomic profiling identifies candidates for targeted interventions such as gene or RNA-based therapies. Multi-omics data also support personalized lifestyle and nutritional recommendations, further enhancing therapeutic effectiveness and patient adherence.

Recent Advances / Emerging Therapies

Recent advances include the use of CRISPR-based genome editing for monogenic cardiac disorders, RNA therapeutics targeting pathogenic transcripts, and cell-based therapies informed by single-cell multi-omics. Integrative analytics and artificial intelligence (AI) facilitate the synthesis of complex multi-omics datasets, enabling real-time clinical application. Liquid biopsy approaches utilizing circulating nucleic acids and exosomes represent minimally invasive modalities for monitoring disease progression and therapeutic response. Ongoing clinical trials are evaluating the efficacy and safety of multi-omics-guided interventions in atrial fibrillation, cardiomyopathies, and coronary syndromes.

Guideline Recommendations

Professional societies, including the American Heart Association (AHA) and European Society of Cardiology (ESC), increasingly recognize the role of multi-omics in precision cardiology. Current guidelines endorse genetic testing for familial cardiomyopathies and channelopathies, and recommend pharmacogenomic assessment in selected patients. However, routine clinical implementation of comprehensive multi-omics profiling awaits further validation, harmonization of analytical platforms, and demonstration of cost-effectiveness. Ongoing efforts aim to incorporate multi-omics data into electronic health records and clinical pathways, facilitating broader adoption in practice.

Conclusion

Multi-omics profiling heralds a new era of individualized cardiac therapy, offering unprecedented opportunities for precision diagnosis, risk stratification, and therapeutic optimization. While significant challenges remain in data integration, interpretation, and clinical translation, ongoing research and technological advances promise to accelerate the adoption of multi-omics-based strategies in cardiology. Clinicians must remain abreast of these developments to harness the full potential of personalized cardiac care and improve patient outcomes.